Ameriprise’s TScan Therapeutics TCRX Stock Holding History

Ameriprise’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.2K	Buy	+52,635	New	+$56.2K	﹤0.01%	4000

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ameriprise's TCRX Position: Q1 2026 in Review

Ameriprise opened a new position in TScan Therapeutics (TCRX) in Q1 2026: 52,635 shares worth $53.2K. The stake represents ﹤0.01% of the portfolio and ranks #4000 among its holdings.

60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Ameriprise held 52,635 shares of TScan Therapeutics worth $53.2K as of Q1 2026.
TScan Therapeutics was a new Ameriprise position in Q1 2026.
TScan Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #4000 holding.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.